Validation of the prognostic grouping of the seventh edition of the tumor-nodes-metastasis classification using a large-scale prospective cohort study database of prostate cancer treated with primary androgen deprivation therapy

Tomokazu Kimura, Mizuki Onozawa, Jun Miyazaki, Koji Kawai, Hiroyuki Nishiyama, Shiro Hinotsu, Hideyuki Akaza

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective: In the TNM seventh edition, a prognostic grouping for prostate cancer incorporating prostate-specific antigen and Gleason score was advocated. The present study was carried out to evaluate and validate prognostic grouping in prostate cancer patients. Methods: The 15259 study patients treated with primary androgen deprivation therapy were enrolled in the Japan Study Group of Prostate Cancer. Overall survival was stratified by tumor-nodes-metastasis, Gleason score and prostate-specific antigen, and extensively analyzed. The accuracy of grouping systems was evaluated by the concordance index. Results: The 5-year overall survival in prognostic grouping-I, IIA, IIB, III and IV was 90.0%, 88.3%, 84.8%, 80.6% and 57.1%, respectively. When considering subgroup stratification, the 5-year overall survival of subgroups prognostic grouping-IIA, IIB, III and IV was 80.9∼90.5%, 75.4∼91.8%, 75.7∼89.0% and 46.9∼86.2%, respectively. When prognostic grouping-IIB was subclassified into IIB1 (except IIB2) and IIB2 (T1-2b, prostate-specific antigen >20, Gleason score ≥8, and T2c, Gleason score ≥8), the 5-year overall survival of IIB2 was significantly lower than that of IIB1 (79.4% and 87.3%, P100 or Gleason score ≥8), the 5-year overall survival of prognostic grouping-IV1 was superior to that of IV2 (72.9% and 49.5%, P

Original languageEnglish
Pages (from-to)880-888
Number of pages9
JournalInternational Journal of Urology
Volume20
Issue number9
DOIs
Publication statusPublished - Sep 2013
Externally publishedYes

Fingerprint

Neoplasm Grading
Androgens
Prostatic Neoplasms
Cohort Studies
Databases
Prospective Studies
Neoplasm Metastasis
Prostate-Specific Antigen
Survival
Neoplasms
Therapeutics
Japan

Keywords

  • Neoplasms staging
  • Primary androgen deprivation therapy
  • Prognostic grouping
  • Prostate
  • Validation studies

ASJC Scopus subject areas

  • Urology

Cite this

Validation of the prognostic grouping of the seventh edition of the tumor-nodes-metastasis classification using a large-scale prospective cohort study database of prostate cancer treated with primary androgen deprivation therapy. / Kimura, Tomokazu; Onozawa, Mizuki; Miyazaki, Jun; Kawai, Koji; Nishiyama, Hiroyuki; Hinotsu, Shiro; Akaza, Hideyuki.

In: International Journal of Urology, Vol. 20, No. 9, 09.2013, p. 880-888.

Research output: Contribution to journalArticle

@article{2a7a73d6c62d44b28681b20527fefeab,
title = "Validation of the prognostic grouping of the seventh edition of the tumor-nodes-metastasis classification using a large-scale prospective cohort study database of prostate cancer treated with primary androgen deprivation therapy",
abstract = "Objective: In the TNM seventh edition, a prognostic grouping for prostate cancer incorporating prostate-specific antigen and Gleason score was advocated. The present study was carried out to evaluate and validate prognostic grouping in prostate cancer patients. Methods: The 15259 study patients treated with primary androgen deprivation therapy were enrolled in the Japan Study Group of Prostate Cancer. Overall survival was stratified by tumor-nodes-metastasis, Gleason score and prostate-specific antigen, and extensively analyzed. The accuracy of grouping systems was evaluated by the concordance index. Results: The 5-year overall survival in prognostic grouping-I, IIA, IIB, III and IV was 90.0{\%}, 88.3{\%}, 84.8{\%}, 80.6{\%} and 57.1{\%}, respectively. When considering subgroup stratification, the 5-year overall survival of subgroups prognostic grouping-IIA, IIB, III and IV was 80.9∼90.5{\%}, 75.4∼91.8{\%}, 75.7∼89.0{\%} and 46.9∼86.2{\%}, respectively. When prognostic grouping-IIB was subclassified into IIB1 (except IIB2) and IIB2 (T1-2b, prostate-specific antigen >20, Gleason score ≥8, and T2c, Gleason score ≥8), the 5-year overall survival of IIB2 was significantly lower than that of IIB1 (79.4{\%} and 87.3{\%}, P100 or Gleason score ≥8), the 5-year overall survival of prognostic grouping-IV1 was superior to that of IV2 (72.9{\%} and 49.5{\%}, P",
keywords = "Neoplasms staging, Primary androgen deprivation therapy, Prognostic grouping, Prostate, Validation studies",
author = "Tomokazu Kimura and Mizuki Onozawa and Jun Miyazaki and Koji Kawai and Hiroyuki Nishiyama and Shiro Hinotsu and Hideyuki Akaza",
year = "2013",
month = "9",
doi = "10.1111/iju.12064",
language = "English",
volume = "20",
pages = "880--888",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Validation of the prognostic grouping of the seventh edition of the tumor-nodes-metastasis classification using a large-scale prospective cohort study database of prostate cancer treated with primary androgen deprivation therapy

AU - Kimura, Tomokazu

AU - Onozawa, Mizuki

AU - Miyazaki, Jun

AU - Kawai, Koji

AU - Nishiyama, Hiroyuki

AU - Hinotsu, Shiro

AU - Akaza, Hideyuki

PY - 2013/9

Y1 - 2013/9

N2 - Objective: In the TNM seventh edition, a prognostic grouping for prostate cancer incorporating prostate-specific antigen and Gleason score was advocated. The present study was carried out to evaluate and validate prognostic grouping in prostate cancer patients. Methods: The 15259 study patients treated with primary androgen deprivation therapy were enrolled in the Japan Study Group of Prostate Cancer. Overall survival was stratified by tumor-nodes-metastasis, Gleason score and prostate-specific antigen, and extensively analyzed. The accuracy of grouping systems was evaluated by the concordance index. Results: The 5-year overall survival in prognostic grouping-I, IIA, IIB, III and IV was 90.0%, 88.3%, 84.8%, 80.6% and 57.1%, respectively. When considering subgroup stratification, the 5-year overall survival of subgroups prognostic grouping-IIA, IIB, III and IV was 80.9∼90.5%, 75.4∼91.8%, 75.7∼89.0% and 46.9∼86.2%, respectively. When prognostic grouping-IIB was subclassified into IIB1 (except IIB2) and IIB2 (T1-2b, prostate-specific antigen >20, Gleason score ≥8, and T2c, Gleason score ≥8), the 5-year overall survival of IIB2 was significantly lower than that of IIB1 (79.4% and 87.3%, P100 or Gleason score ≥8), the 5-year overall survival of prognostic grouping-IV1 was superior to that of IV2 (72.9% and 49.5%, P

AB - Objective: In the TNM seventh edition, a prognostic grouping for prostate cancer incorporating prostate-specific antigen and Gleason score was advocated. The present study was carried out to evaluate and validate prognostic grouping in prostate cancer patients. Methods: The 15259 study patients treated with primary androgen deprivation therapy were enrolled in the Japan Study Group of Prostate Cancer. Overall survival was stratified by tumor-nodes-metastasis, Gleason score and prostate-specific antigen, and extensively analyzed. The accuracy of grouping systems was evaluated by the concordance index. Results: The 5-year overall survival in prognostic grouping-I, IIA, IIB, III and IV was 90.0%, 88.3%, 84.8%, 80.6% and 57.1%, respectively. When considering subgroup stratification, the 5-year overall survival of subgroups prognostic grouping-IIA, IIB, III and IV was 80.9∼90.5%, 75.4∼91.8%, 75.7∼89.0% and 46.9∼86.2%, respectively. When prognostic grouping-IIB was subclassified into IIB1 (except IIB2) and IIB2 (T1-2b, prostate-specific antigen >20, Gleason score ≥8, and T2c, Gleason score ≥8), the 5-year overall survival of IIB2 was significantly lower than that of IIB1 (79.4% and 87.3%, P100 or Gleason score ≥8), the 5-year overall survival of prognostic grouping-IV1 was superior to that of IV2 (72.9% and 49.5%, P

KW - Neoplasms staging

KW - Primary androgen deprivation therapy

KW - Prognostic grouping

KW - Prostate

KW - Validation studies

UR - http://www.scopus.com/inward/record.url?scp=84883463277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883463277&partnerID=8YFLogxK

U2 - 10.1111/iju.12064

DO - 10.1111/iju.12064

M3 - Article

VL - 20

SP - 880

EP - 888

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

IS - 9

ER -